Email This Release
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire